HDL-C in Cardiac Syndrome X

Completed

• Conditions: Cardiovascular Diseases; Heart Diseases; Myocardial Ischaemia; Unstable Angina; Microvascular Angina

• Registration Number: NCT02095964
• Lead Sponsor: Bursa Yüksek İhtisas Education and Research Hospital

Brief Summary

High density lipoprotein cholesterol (HDL-C) is in the centrum of the process of reverse cholesterol transport from peripheral cells to the liver\[10\]. HDL-C promotes endothelial generation of nitric oxide (NO) and improves endothelial function and arterial vasoreactivity\[11\]. In several studies, lower HDL-C level was reported to be associated with increased coronary artery disease (CAD) risk\[12-14\]. HDL-C also has anti- inflammatory and anti-oxidant activities\[15,16\]. Concerning anti-inflammatory activity, HDL-C inhibits the activation of monocytes/macrophages and neutrophils\[17,18\] and inhibits the expression of endothelial adhesion molecules, such as vascular cell adhesion molecule-1 (VCAM-1) and E-selectin\[15\].

In this study we aimed to investigate the relation of HDL-C level with systemic inflammatory markers in patients with cardiac syndrome X (CSX).

Detailed Description

Not available

Study Timeline

• Study Start: 2012-03
• Primary Completion: 2013-12
• Study Completion: 2014-01
• Status Verified: 2014-03
• Study First Submitted: 2014-03-17
• Study First Submitted QC: 2014-03-24
• Last Update Submitted: 2014-03-24
• Study First Posted: 2014-03-26
• Last Update Posted: 2014-03-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 710

Inclusion Criteria

• Must be able to get exercise stress test
• Must be able to have coronary angiography
• Clinical diagnosis of typical anginaduring rest or effort
• Abnormal test result for exercise ECG or myocardial perfusion scintigraphy
• Must have of angiographically normal epicardial coronary arteries

Exclusion Criteria

• Patients with valvular heart disease (mitral stenosis and moderate to severe mitral regurgitation
• Patients with moderate to severe aortic stenosis and regurgitation including mitral annular calcification)
• Patients with heart failure (left ventricular ejection fraction <50%)
• Patients with congenital heart disease, cardiomyopathy, left ventricular hypertrophy, right ventricular hypertrophy
• Patients with cardiac surgery
• Patients with thyroid disease
• Patients with anemia
• Patients with pulmonary diseases
• Patients with infectious diseases (locally or systemic)

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
HDL-Cholesterol	6 MONTHS	HDL-Cholesterol \<40 mg/dL(male) / \< 50mg/dL(female) ==\> low HDL-C
Cardiac Syndrome X	6 months	Patients who have typical anginal chest pain+ischaemic findings at exercise stress test/myocardial scintigraphy + normal epicardial coronaries at coronary angiography ==\> Cardiac syndrome X
Inflammation	6 months	CRP \> 2,98 mg/dL ==\> systemic inflammation